$Aprea The_老虎社区_美港股上老虎

2020-12-30

$Aprea Therapeutics, Inc.(APRE)$因此，Renza将Apreas的评级从“跑赢”（即买入）下调至“行业表现”（即持有），并将目标价从40下调至10。尽管如此，在股价大幅下挫之后，仍有较目前水平大幅上涨98%的潜在空间。（要看伦扎的记录，点击这里）

Don’t Go Bargain Hunting on Aprea Stock, Says Analyst

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

mingmingfu
2020-12-30
mingmingfu
所以这个股票已经到底了吧？
- mingmingfu回复TheWorld:
  谢谢！我已经入坑了
- TheWorld:
  未必，慎重，医药暴跌，看过好多都是要么暴跌那天拉上来，之后几天上涨之后横盘，要么是暴跌当天拉不起来，接着连跌几天，之后横盘。
  最终很多都是横盘几个月，然后垂死病中惊坐起，冲上天。
  不过买这种暴跌的都是博那个暴涨吧？？
  相对而言毛票这种情况常见，这种还有几块的就不知道未来怎么走了，反正横盘的话没个两三个月以上变化一般不大

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":333254885,"tweetId":"333254885","gmtCreate":1609295773747,"gmtModify":1703738648784,"author":{"id":3569930970566883,"authorId":3569930970566883,"authorIdStr":"3569930970566883","name":"晶晶大虎","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/APRE\">$Aprea Therapeutics, Inc.(APRE)$</a>因此，Renza将Apreas的评级从“跑赢”（即买入）下调至“行业表现”（即持有），并将目标价从40下调至10。尽管如此，在股价大幅下挫之后，仍有较目前水平大幅上涨98%的潜在空间。（要看伦扎的记录， 点击这里）</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/APRE\">$Aprea Therapeutics, Inc.(APRE)$</a>因此，Renza将Apreas的评级从“跑赢”（即买入）下调至“行业表现”（即持有），并将目标价从40下调至10。尽管如此，在股价大幅下挫之后，仍有较目前水平大幅上涨98%的潜在空间。（要看伦扎的记录， 点击这里）</p></body></html>","text":"$Aprea Therapeutics, Inc.(APRE)$因此，Renza将Apreas的评级从“跑赢”（即买入）下调至“行业表现”（即持有），并将目标价从40下调至10。尽管如此，在股价大幅下挫之后，仍有较目前水平大幅上涨98%的潜在空间。（要看伦扎的记录， 点击这里）","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/333254885","repostId":2095721905,"repostType":2,"repost":{"id":"2095721905","pubTimestamp":1609287897,"share":"https://www.laohu8.com/m/news/2095721905?lang=&edition=full","pubTime":"2020-12-30 08:24","market":"us","language":"en","title":"Don’t Go Bargain Hunting on Aprea Stock, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2095721905","media":"TipRanks","summary":"The stock market is often witness to extreme stock gyrations, though hardly any more so following th","content":"<div>\n<p>The stock market is often witness to extreme stock gyrations, though hardly any more so following the impact of clinical trial results – good or bad.\nUnfortunately for Aprea Therapeutics (APRE), the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/don-t-bargain-hunting-aprea-002457187.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Don’t Go Bargain Hunting on Aprea Stock, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDon’t Go Bargain Hunting on Aprea Stock, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-12-30 08:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/don-t-bargain-hunting-aprea-002457187.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market is often witness to extreme stock gyrations, though hardly any more so following the impact of clinical trial results – good or bad.\nUnfortunately for Aprea Therapeutics (APRE), the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/don-t-bargain-hunting-aprea-002457187.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/QBGE2Wowdy6q2OTAjNDgMA--~B/aD00MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/h5yeOm7Va_oWkr_FKMkAxA--~B/aD00MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en-US/tipranks_452/d3beb91bad460d624febb1815b2fd0ff","relate_stocks":{"APRE":"Aprea Therapeutics, Inc."},"source_url":"https://finance.yahoo.com/news/don-t-bargain-hunting-aprea-002457187.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2095721905","content_text":"The stock market is often witness to extreme stock gyrations, though hardly any more so following the impact of clinical trial results – good or bad.\nUnfortunately for Aprea Therapeutics (APRE), the stock’s latest move was down to the latter.\nThis week, Aprea shares cratered by 80% (yes, 80), after the biopharma’s lead therapeutic candidate failed to impress in a late-stage trial.\nSpecifically, in the Phase 3 trial of MDS (myelodysplastic syndrome) treatment eprenetapopt, the drug failed to meet the primary endpoint of complete remission (CR).\nWhile the drug’s results improved on those of the control arm, they failed to do so in a statistically significant manner (33% vs 22.4%).\nAs the baseline characteristics were similar to those of the Phase 1 and 2 studies, the company is now further analyzing the data to understand the CR rate’s ~70% drop.\nMeanwhile, focus will turn to other programs in Aprea’s pipeline, including in AML (acute myeloid leukemia), CLL (chronic lymphocytic leukemia), and solid tumors. \nBut for RBC analyst Gregory Renza, the damage is done, and the results necessitate a rejig of his Aprea model.\n“While the company continues to proceed with other pipeline programs around eprenetapopt, we believe the news has an adverse read-through to the path forward and lowers our confidence in the potential of the molecule and the programs,” the 5-star analyst said. “We look to the data updates from the programs in 2021 for additional insights into the activity of epr and APR-548 in other indications, though we believe the MDS PE miss reads through to the earlier pipeline programs and lowers our expectation on the data readouts.”\nAccordingly, Renza downgraded Aprea’s rating from Outperform (i.e. Buy) to Sector Perform (i.e. Hold) and slashed the price target from $40 to $10. That said, following the sharp share decline, there is still potential upside of a hefty 98% from current levels. (To watch Renza’s track record, click here)\nWall Street believes Renza is smart to play it safe when it comes to the Aprea's prospects ahead, as TipRanks analytics reveal the stock as a Hold. Out of 5 analysts polled in the past week, four say Hold, while only one suggests Buy. With a potential upside of 46%, the consensus price target stands at $7.40. Yet, the analysts are not convinced the reward is worth all the risk. (See APRE stock analysis on TipRanks)\n\n\n\n\n\nTo find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.\nDisclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1149,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["APRE"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":207,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":3253219,"gmtCreate":1609314395117,"gmtModify":1609314395117,"authorId":3554508354296342,"author":{"id":3554508354296342,"authorId":3554508354296342,"name":"mingmingfu","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":333254885,"type":1,"supId":0,"prevId":0,"content":"所以这个股票已经到底了吧？","text":"所以这个股票已经到底了吧？","html":"所以这个股票已经到底了吧？","likeSize":0,"commentSize":2,"subComments":[{"id":3253515,"gmtCreate":1609320177934,"gmtModify":1609320177934,"authorId":3554508354296342,"author":{"id":3554508354296342,"authorId":3554508354296342,"name":"mingmingfu","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3498032310834282,"repliedAuthor":{"id":3498032310834282,"authorId":3498032310834282,"name":"TheWorld","avatar":"https://static.tigerbbs.com/1bf08ecbcdb9e3ebc88cbcf70a1731e2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":333254885,"type":1,"supId":3253219,"prevId":3253284,"content":"谢谢！我已经入坑了","text":"谢谢！我已经入坑了","html":"谢谢！我已经入坑了"},{"id":3253284,"gmtCreate":1609316116016,"gmtModify":1609320056890,"authorId":3498032310834282,"author":{"id":3498032310834282,"authorId":3498032310834282,"name":"TheWorld","avatar":"https://static.tigerbbs.com/1bf08ecbcdb9e3ebc88cbcf70a1731e2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":333254885,"type":1,"supId":3253219,"prevId":0,"content":"未必，慎重，医药暴跌，看过好多都是要么暴跌那天拉上来，之后几天上涨之后横盘，要么是暴跌当天拉不起来，接着连跌几天，之后横盘。<br>\n最终很多都是横盘几个月，然后垂死病中惊坐起，冲上天。<br>\n不过买这种暴跌的都是博那个暴涨吧？？<br>\n相对而言毛票这种情况常见，这种还有几块的就不知道未来怎么走了，反正横盘的话没个两三个月以上变化一般不大","text":"未必，慎重，医药暴跌，看过好多都是要么暴跌那天拉上来，之后几天上涨之后横盘，要么是暴跌当天拉不起来，接着连跌几天，之后横盘。<br>\n最终很多都是横盘几个月，然后垂死病中惊坐起，冲上天。<br>\n不过买这种暴跌的都是博那个暴涨吧？？<br>\n相对而言毛票这种情况常见，这种还有几块的就不知道未来怎么走了，反正横盘的话没个两三个月以上变化一般不大","html":"未必，慎重，医药暴跌，看过好多都是要么暴跌那天拉上来，之后几天上涨之后横盘，要么是暴跌当天拉不起来，接着连跌几天，之后横盘。<br>\n最终很多都是横盘几个月，然后垂死病中惊坐起，冲上天。<br>\n不过买这种暴跌的都是博那个暴涨吧？？<br>\n相对而言毛票这种情况常见，这种还有几块的就不知道未来怎么走了，反正横盘的话没个两三个月以上变化一般不大"}],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/333254885"}